๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Thermo Fisher Scientific Inc. (TMO)
NYSE: TMO ยท Real-Time Price ยท USD
669.54
-19.21 (-2.79%)
At close: Nov 20, 2026, 4:00 PM EST
669.54
0.00 (0.00%)
After-hours: Nov 20, 2026, 7:00 PM EST
โ† View all transcripts

UBS 2026 CEO Call Series

Nov 19, 2026

Summary

Markets are strengthening, with pharma and biotech leading the recovery and academic spending expected to improve in 2027. The 2026โ€“2027 organic growth range remains 3%โ€“6%, with a 7% objective for 2028 and AI, reshoring and China as potential tailwinds.

Operator

Welcome to today's call. Please remain muted throughout the call. If you'd like to ask a question, please use the raise hand icon found in the black bar at the bottom of the screen. When called on, you may unmute and ask your question. Doug Schenkel, you may begin.

Doug Schenkel
Managing Director and Analyst, UBS

All right. Thanks, Luca. Good day, everyone. My name is Doug Schenkel, and on behalf of my UBS colleagues, it's my pleasure to welcome Marc Casper, the Chairman and CEO of Thermo Fisher Scientific, to the UBS CEO Call Series. Marc, it's good to see you, and thank you for taking the time today.

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Doug, likewise. Great to see you. Happy holidays, and I'm very much looking forward to the dialogue.

Doug Schenkel
Managing Director and Analyst, UBS

All right. Well, that's great. We are as well, and we had a lot to cover in a short period of time. Lots of exciting things to go through over the next 30 minutes. That said, for those of you listening in, I will try to work in any questions you have. Some of you have already emailed me. If there's additions you want me to weave in, email me at doug.schenkel@ubs.com. With that said, maybe we can start with a state of the union, Marc. Thermo has a unique perspective across the industry, given the breadth of your portfolio and customer relationships. As you reflect on 2026 and how that's played out so far, what are you seeing in terms of customer activity and end market conditions heading into year-end, and then how does that shape your perspective as we look ahead to 2027 and beyond?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah. Doug, super exciting time, in terms of at the company, in the markets that we serve, and ultimately the performance that we're delivering and will expect to continue to deliver. When I think about the context, I'll spend a minute on the company and then a minute on the end markets, and I'm sure we'll get into many other questions. From a company perspective, Q3 was really an excellent quarter. The year's playing out very well in terms of performance. We were ahead of expectations, and throughout the year, we've been able to raise our outlook on the top and bottom line. I feel good about that. The strategy is resonating well in terms of driving growth and share gain and ultimately converting that into strong financial performance in the middle of the P&L and the bottom line as well. End markets.

I'll make kind of two macro points. They're behaving more predictably, right. If you think about, both you and I have been in this industry a very long time, and that's a good thing from a context standpoint. For most of the years, actually, this is an industry where fairly predictable, right, in terms of how the end markets were. There was always a little bit of puts and takes on some specific issue, but very much a predictable end market and one that has great drivers of growth. That has allowed for companies to really be able to have a very predictable outlook. We've gone through a period of three or four years where, both on the upside and the downside, there was less predictability.

In 2025, we were able to articulate fairly early in the year how we saw the next few years progressing from an end market perspective and what we thought would happen. That predictability has come back because the markets are actually playing out the way that we articulated it and continue to progress in a good direction. In terms of what we're seeing, you've seen pharma and biotech continue to strengthen. Biotech funding has improved, and that customer base is spending, so that was an area of headwind in that sort of 2024-type timeframe, and you've seen that improve and is on a trajectory to continue to improve. You definitely have seen academic and government stabilize, right.

Still a muted environment, but relative to a year ago, where there were a lot of policy discussions that really froze type spending, if you will, in terms of sentiment, that's picked up. End market's progressing well, and I feel good about our outlook in terms of the markets continuing to strengthen and reverting to kind of normal long-term growth by the time we're in 2028. Really exciting time.

Doug Schenkel
Managing Director and Analyst, UBS

All right. That's a great place to start, and I know we'll unpack a decent amount of that more as we progress through this discussion. Before we do that, there's been a lot of focus on the U.S. outlook right now coming off of the midterm elections and the blue wave. A lot of investors are asking about things like MFN and maybe a better academic government spending environment, maybe the psychology getting a little bit better after the election. Recognizing it's only been a couple of weeks, so I want to try to be fair about this, but it is obviously something in focus. What are your thoughts on the election and how that impacts things heading into 2027?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah. What I would say is that our expectation is that it's constructive, that from an NIH funding perspective, which is very important to U.S. academic spend, actually, both parties have similar views within Congress. Administration has some different views on that. So, in our meetings even before the election with Democratic leadership, there's a high level of commitment to the importance of NIH, and so I feel good about that. I also think just with split government, you wind up tamping down some of the noise that has really been the single biggest headwind for academic spend in the U.S., right. It really hasn't been funding. Funding's been okay. It's not fabulous, but it's okay. In terms of the funding, the funding's been okay, but the spend has been cautious because there's always a "will it stop" kind of environment.

I think actually this should contribute to more stability and returning to growth in 2027 within that end market, which is a good part of the progression we would expect. On pharma, at least in the sentiment with our customers, I don't think anyone sees this as a high agenda item in the short term, in terms of focus, and that the MFNs and some of the other things that have happened are well-characterized, and it's really an exciting time for that industry. So, I would say it's constructive and slightly positive.

Doug Schenkel
Managing Director and Analyst, UBS

Okay. No reason to think that there's material changes in how we've been thinking about reshoring?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

No, I think that is pretty much the companies have made commitments, and a lot of the underlying drivers actually made sense in terms of the market is here, the profit in the industry is here, having a level of production here is a logical place to go.

Doug Schenkel
Managing Director and Analyst, UBS

Maybe building off of that, let's spend a few minutes on, more broadly, the pharma and biotech end market. You talked about this a little bit earlier. It's important for us to maybe double-click here, given it's about 60% of your revenue. We've seen improving customer activity. It seems like large pharma is continuing to invest in drug development, partly to prepare for patent expirations later this decade, but also because this is what they do. Biotech funding's also been better. Our analysis demonstrates that funding has about doubled year-over-year in terms of new money going into the end market. As we look at the number of new drug approvals, an argument can be made that the FDA is actually a bit more accommodating than it's been the last few years.

With all of that in mind, how are you seeing these dynamics play out across preclinical research and clinical development, and then how do you think about the trajectory of R&D investment over the next few years?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah. So, Doug, first, start with our performance, right. In the third quarter, we grew high single digits serving pharma and biotech. Our performance in that market continues to strengthen, and we feel very good about the health of the end market. We're not at the peak at all, right. We're in the recovery, and you're seeing that translate into a real step up in growth. When I think about how you would characterize the two big end markets here, pharma and biotech, I agree. On the pharma side, you're seeing companies excited by the science, investing in R&D, and really thinking about their pipelines and do they have the right pipeline for the future. So, it is a very dynamic time and a very positive time in terms of that end market. Biotech funding has improved. We talked early in 2025 about sentiment improving.

As 2025 progressed, we saw activity improve. Now you're seeing good growth, and that's strengthening. As I interact with this customer base and our management team does, you're seeing a much higher degree of confidence. If you have good science, you're progressing through the pipeline, through the various development stages, customers have confidence they're going to get funding, right. That creates a much more positive dynamic, and one of the things that will continue to drive strengthening of growth in our end markets and ultimately our position. When I think about where spending is more concentrated in biotech, you're still seeing it more in the later stage as they're developing their pipeline, going through the development milestones so they can capture more funding. We would expect the next place for spending to increase is in the early research side as they refill their pipeline with scientific research.

We're starting to see a pickup in that segment within our Fisher Scientific channel, the basic lab supplies and expansions, and we would expect our reagent businesses, the higher tech portion of the portfolio, to improve as well through the cycle. I think the other driver here is around AI, and you're seeing a tremendous excitement about how AI can improve the returns for the pharmaceutical and biotech industry because of getting higher returns on the R&D investments, and that is also a driver of the outlook for the business, which we think is very strong in terms of a strengthening end market and one with strong growth for us.

Doug Schenkel
Managing Director and Analyst, UBS

Pivoting on end markets, we talked a little bit about academic and government when we were discussing the election. It was helpful on the Q3 call to get your perspective on the direction of travel for NIH funding in the U.S. Globally, what are you seeing more broadly across the academic and government end market? If there's anything to add on the U.S., that's great, but internationally, how are you seeing things trending given the environment, some good and some bad?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah. So, if you say start with the results, flat growth in Q3. For the year, our expectation is slight decline. With the U.S. dynamic and an improving outlook in China, I would expect that this market starts to revert back to a more normalized growth, low single digits. I think if there's other pressures on government spending and budgets more broadly, that will say it's not going to be amazingly robust, but I think we go from the declines, starting to get to a period where you're back to that low single-digit growth as we progress over the next couple of years. So I think that's a positive. Nothing really significant to call out by geography outside the U.S.

What I would say is the thing that has always been true for us is when we bring out really innovative, high-tech instruments, irrespective of the funding environment, demand is strong, right. If you think about how well our Orbitrap franchise of mass spectrometers are doing, how well our electron microscopes are doing, in this customer set, effectively, customers will get the money irrespective of the environment because they're literally wasting their time if they don't have the cutting-edge tools, right. Because maybe some other lab is more equipped to be able to drive scientific insights. So, it is a positive. So innovation is incredibly important to us. We talk about it on every earnings call, and that's allowed us to navigate this environment, I think, quite effectively.

Doug Schenkel
Managing Director and Analyst, UBS

Yeah, even in a difficult environment, right? These labs need to compete for talent. They need to compete for paper. So, the innovation that you're bringing to market matters, regardless of market. Maybe we can touch on China for a moment. You delivered strong growth in the quarter. I think you guys are up low double digits, which was really encouraging. Others in the group sound more positive, especially when it comes to the biopharma end market in China.

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Sure.

Doug Schenkel
Managing Director and Analyst, UBS

Can you talk about what is driving your improved performance, how you're thinking about the outlook in China? Sorry for the long question, but layer in one more component to this. Your longer-term framework, I think, assumes growth below the corporate average in the region. Keeping in mind some of the improvement, what would you need to see to become more constructive on the long-term opportunity in China?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah. So, what we articulated both in the middle of last year and again at our Investor Day around China, which was in May, the business is about 7.5% of our revenue. We've been a leader in the market for many years, over 40 years of presence, a very scaled presence, very strong customer relationships. You think about the environment, government has not really focused on fiscal spending, so in terms of even much of an austerity-type approach to navigating their economy. So, it's a large chunk of the economy has been fairly muted. The positive parts of the end market were pharma and biotech and semiconductor. What we assumed and/or embedded into our outlook was that China would be a slight drag relative to the company's average growth.

Part of it is, I think there's not a lot of benefit of being overly bullish on China. We measure our performance whether we're doing well or not, so we're not going to lower our aspirations. The last two quarters, you've seen the end market improve and our performance improve. The low double-digit growth is a real positive. It's driven by pharma and biotech, and we've seen very strong growth there. We've seen very strong growth in supporting the semiconductor industry with our electron microscopes. Our expectation is that it's more likely that our assumptions around China could be conservative over the next couple of years, and it could actually be an upside. So, even the way we framed it in sort of how we built out the outlook, we said China could be an upside.

My view, just having served the market a long time and worked in the market, I wouldn't take a quarter or two as a trend yet. I would just say it's good data points to have some optimism. We're well-positioned to capitalize on it, and could be an upside as we get into the trajectory for the next couple of years.

Doug Schenkel
Managing Director and Analyst, UBS

Okay. Let's switch gears and spend a few minutes on the divisions, the individual businesses, starting with Life Sciences Solutions. From an external perspective, performance in the quarter came in what was otherwise a really solid quarter, this is where things were maybe a little bit below expectations. Keeping in mind this is where you have bioproduction, biosciences, and genetic sciences, it would be helpful to understand what you're seeing across each of these businesses and how you think about progression from here.

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah. So when I think about Life Sciences Solutions, three businesses, as you articulated, actually very strong competitive positions.

Doug Schenkel
Managing Director and Analyst, UBS

Right.

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Across all three. When I think about each of the businesses, bioproduction, leading capabilities in terms of cell culture media, single-use technologies, a rapidly growing purification business, and we just anniversaried our filtration acquisition, and that's off to a good start in the first year. I always think of that business as a high single-digit, low double-digit growth of bioproduction in aggregate. We've been growing meaningfully faster than that as the market has improved. So we have a little bit more challenging comparisons relative to others, and our expectation is that over the next couple of quarters, you'll see the impact of that, but you'll see that business over this period of time being that longer period of time being high single-digit, low double-digit growth. Biosciences and genetic sciences, I'll put them together in terms of what's driving them.

Reasonable exposure to academic end markets and a meaningful exposure to the early research portion of biotech. So the end market there is softer. You can see that in the results across the industry. We're starting to see the green shoots there, and our expectation is as we get, as 2027 progresses, you'll see the end markets improve for that business, and ultimately growth will strengthen meaningfully. It's a very profitable business, so it's a good driver of our earnings, so we're excited for that. It's behaving the way we would expect, meaning that if I think about the pharma and biotech cycle and how the different end markets recover, you would see effectively the early research recover last, and we've talked about this over the last few years. That's playing out the way we would expect it to play out, and we feel good about our competitive position.

Doug Schenkel
Managing Director and Analyst, UBS

Analytical Instruments, you actually had a really strong quarter with results meaningfully ahead of expectations. What drove the outperformance, and how do you think about the outlook for this segment from here?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah, we had a really strong quarter in terms of mid-single-digit growth. We had excellent performance in our electron microscopy and chromatography and mass spectrometry business in the quarter. Innovation really mattered here. Throughout the year, you've heard us talk about a large number of launches. We launched a new Orbitrap mass spectrometer, really strong demand, electron microscopy performing very well. The end markets are improving, and one of the linkages between this business and the Life Sciences Solutions business is what we're doing in proteomics. If you think about our Olink business and Life Sciences Solutions, you think about our mass spectrometry business, we're seeing very strong demand for biobanking studies, really to get at the fundamental identification of disease and the causes of disease before it happens.

You saw us announce a collaboration and the formation of a new company with the Mayo Clinic. It's called PreCure, and it really is exactly what the company name is. It's really about identifying from over a million biological samples what's going on in a body before it presents as a disease, and therefore, you can start to have really preventive medicine that really will be relevant to patients, and a hugely exciting time.

Doug Schenkel
Managing Director and Analyst, UBS

Pharma services, another area where you had really strong performance in the quarter, again, ahead of expectations. What drove that outperformance? Can you walk us through that, and then again, give us the look-forward view on pharma services?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah, Doug, if I think about the pharma services business, leading contract development and manufacturing organization, we play as the leader in the clinical trials packaging and logistics, a meaningful position in drug product, primarily in the sterile fill-finish area, as well as in drug substance, both high-value API and on biologics. When I think about the year in aggregate, it's actually playing out the way that we expect it to. It's a good growth business. We expected that it was going to be based on production schedules and the campaigns we were running. Growth would be stronger in the second half than the first, and the third quarter was very strong growth. Some of it was we got work done and campaigns completed a little bit faster than the fourth quarter.

So, what we would expect is a strong year in pharma services with good growth, and the trends of like reshoring, this business benefits from that. We won a lot of contracts to produce medicines in the U.S. to help our customers meet the obligations they have to the U.S. government. So, we have a unique position, and we feel good about the performance there. What I would also say is that we have benefited from our Accelerator Drug Development capabilities, which is really focused on time. And the insights we have from our clinical research business and our pharma services business has allowed us to have an offering that we can help our customers bring medicines to market more quickly, and then ultimately, that really is winning a lot of business for us.

Doug Schenkel
Managing Director and Analyst, UBS

A quick follow-up as you talked about clinical research. I mean, that side of the business appears to be on track to deliver mid-single-digit growth this year. What does the strength of your book-to-bill tell you about the potential for even stronger growth in 2027? And maybe while we're talking about this, how's the Clario integration progressing?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah, so clinical research is performing well. Our authorizations or new wins has been exceeding revenue and actually behaving the way we would expect, meaning that you would expect as funding has improved in biotech, you're seeing the wins, you're seeing pharma. We've talked about how we see their R&D spending increasing. So, we're seeing that activity pick up. You're seeing revenue, as you said, in that mid-single-digit range of growth. And we would expect that that business is continuing to strengthen, and then ultimately, we see that as a mid to high single-digit long-term growth business. And I put that larger range because there's some cycle to it right now, so I would expect we're working our way up towards the high single-digit growth part, but in the long term, it bounces between the two.

Accelerator Drug Development helps here meaningfully. The Clario acquisition has been about seven, eight months at this point since we closed it. It's off to a good start. Customers understand what we're trying to do. It is a platform that sites that do clinical research use to basically manage their endpoint generation, and we are investing heavily in the technology so that we can support every CRO or even individually sponsored from one of the large pharma companies, that we have ultimately the best technology and will play a very important role in the clinical development process through Clario. So, it's an AI-enabled technology, and ultimately, we think it's going to be a really high-growth, very profitable business for Thermo Fisher.

Doug Schenkel
Managing Director and Analyst, UBS

All right. Good segue with the reference to AI. I want to spend a couple minutes here. At your Investor Day back in May, you were one of the first in the industry to talk about AI as a potential tailwind for life sciences and Thermo specifically. Since then, we've seen growing interest from pharma and biotech customers, and the broader industry narrative around AI has become increasingly positive. Where do you see the biggest opportunities for Thermo, and why are you well-positioned to capture them, and when will this actually translate into more meaningful growth?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah. Doug, when I think about firstly end market, pharma and biotech are super excited about it, right. And they are investing, they're deploying the technology from early research through development to be able to effectively have better pipelines and better returns on their activity. And it's palpable in every discussion, and we are side by side with them in many areas, bringing thought leadership in many areas, learning with our customers, and super exciting. When I think about why we win, we have more data than anybody else. We have the ability to link the activities across the value chain, just given the nature of our portfolio, in ways that nobody else has these capabilities, and we do it at scale.

When you think about, we have a business that we've dedicated to effectively autonomous and intelligent laboratories, pull together our resources to serve that trend in early research, where you're seeing how science is being conducted in a very different way. Super exciting. You see it in deploying it very aggressively in our CRO, in the development activities to develop better trials, more cost-effective, and ultimately higher quality. It is a super exciting time, and we're all in on helping our customers be successful and ultimately benefiting from the transformation that's going on.

Doug Schenkel
Managing Director and Analyst, UBS

Yeah, it sounds like more customer spending, more share gains, and more productivity, all of the above, right?

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

That's the plan.

Doug Schenkel
Managing Director and Analyst, UBS

Yeah. Okay. In closing, Marc, maybe stepping back, you've led Thermo through a number of different market cycles. You have unique perspective on the industry. As you look ahead, how confident are you in the building blocks supporting your midterm growth framework, including progressing toward the high end of your 3%-6% organic growth range in 2027 specifically, and then ultimately achieving your longer-term objective of 7%? Again, I don't think you're putting a cap on things, so I just want to make sure we're talking about confidence and progression into 2027 and beyond.

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Yeah. We feel that the 3%-6% outlook that we talked about in 2025 for these couple years, this year and next, makes sense, and that we're seeing progression, meaning we'll grow 4% this year as a company, basically, with 5% in the second half. So, we would see that 2027, we'll still operate in that range, but we'll strengthen from this year, would be our view, and we'll give our guidance in early February. The building blocks of stronger biotech, stabilization in academic, really potential upsides from reshoring, AI, as examples, and even China. Our investors a long time ago said 7% is a good place to take away all the pluses and all the things from that and just focus on delivering that for 2028. But we're not capped at all.

We're excited about our industry and our position, and we're always going to set goals where, when we deliver them, our investors will say, "You actually, you really did a really good job in terms of share gain and performance." So, super exciting time in our end market and at our company.

Doug Schenkel
Managing Director and Analyst, UBS

All right, Marc, I could sit here with you all day and talk about these things, but I know we got to let you run the business. We really appreciate you taking the time. This has been fantastic. We'll talk to you soon, and happy holidays to you and everybody on the line.

Marc Casper
Chairman and CEO, Thermo Fisher Scientific

Doug, thanks so much, and thanks for doing this. Bye-bye.